Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Trial details
- Registry ID
- NCT05714345
- Phase
- Phase 2
The FDA approved Cyclophosphamide (Cytoxan®) on 16 Nov 1959.
Drug identity checked against registry records
Also recorded as Cytoxan®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyNCT05714345 | Allogene Therapeutics | Phase 2 | Terminated | 2024-02-20Actual |
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514 | Actinium Pharmaceuticals | Phase 2, Phase 3 | Not yet recruiting | 2029-02Estimated |
| Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399 | IBRX | Phase 2 | Active not recruiting | 2025-10-13Actual |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612 | BriaCell Therapeutics Corporation | Phase 3 | Recruiting | 2027-12Estimated |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLNCT06500273 | Allogene Therapeutics | Phase 2 | Recruiting | 2027-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1959-11-16Day | Cyclophosphamide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA012141", "applicant_as_listed_by_fda": "BAXTER HLTHCARE", "brand_names": ["CYTOXAN"], "active_ingredients": ["CYCLOPHOSPHAMIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19591116", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |